ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

VETOSPIRIN 1000 mg/g powder for use in drinking water/milk for cattle and pigs (NL, BE, DE, EE, ES, HU, LV, LT, PL, PT, RO)
VETOSPIRINE 1000 mg/g powder for use in drinking water/milk (FR)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each gram contains:
Active substance:sodium salicylate 1000 mg
equivalent to 863 mg salicylic acid.

White crystalline powder or small colourless flakes

3. CLINICAL INFORMATION

3.1 Target species

Cattle (calves), pigs

3.2 Indications for use for each target species

Calves: Supportive treatment of pyrexia in acute respiratory disease, in combination with appropriate (e.g. anti-infective) therapy if necessary.
Pigs: For the treatment of inflammation in combination with appropriate (e.g. anti-infective) therapy if necessary.

3.3 Contraindications

Do not use in case of severe hypoproteinaemia, liver or kidney disorder
Do not use sodium salicylates in neonates or calves less than 2 weeks of age.
Do not use in piglets of less than 4 weeks of age.
Do not use in cases of hypersensitivity to the active substance.
Do not use in case of gastrointestinal ulcerations and chronic gastrointestinal disorders.
Do not use in case of malfunction of the hematopoietic system, coagulopathies, haemor-rhagic diathesis.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:
Given that sodium salicylate may inhibit clotting of blood, it is recommended that elective surgery should not be performed on animals within 7 days after the end of treatment.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
This veterinary medicinal product may cause hypersensitivity reactions. People with known hypersensitivity (allergies) to sodium salicylate or related substances (e.g. aspirin) should avoid contact with the veterinary medicinal product. Wash hands after use.
If after accidental contact rash occurs, seek medical advice and show the package leaflet. Swelling of the face, lips or eyes or difficulty in breathing are more serious symptoms that require urgent medical attention.

Do not smoke, eat or drink during handling.

This veterinary medicinal product may cause irritation of the skin, eyes and respiratory tract. Direct contact with the skin and eyes, and inhalation of the powder should be avoided. It is recommended to wear protective gloves (e.g. rubber or latex), safety glasses, and an appropriate dust mask (e.g. disposable half-mask respirator conforming to European Standard EN149). In case of accidental dermal exposure wash skin immediately with water. In the event of accidental eye contact wash the eyes with plenty of water for 15 minutes and seek medical advice if irritation persists.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Cattle (calves) and pigs:

Undetermined frequency (cannot be estimated from available data) :	Gastrointestinal irritation[A] ,Tarry or black stool, Digestive tract haemorrhage Polydipsia Prolonged bleeding [B]

[A] Especially in animals with pre-existing gastro-intestinal disease.
[B] Reversible inhibition of normal blood clotting; effect will diminish within approximately 7 days

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Do not use during pregnancy and lactation.
Laboratory studies in rats have shown evidence of teratogenic and foetotoxic effects.
Salicylic acid penetrates the placenta and is excreted in the milk. Since the half-life in new-borns is longer, symptoms of toxicity may occur much faster. In addition, the aggregation of platelets is slowed down and the bleeding time is prolonged, which is an unfavourable situation during dystocia or caesarean section. Some studies also indicate that delivery is delayed.

3.8 Interaction with other medicinal products and other forms of interaction

Concurrent administration of potentially nephrotoxic drugs (e.g. aminoglycosides) should be avoided.

Salicylic acid is highly plasma (albumin) bound and competes with a variety of compounds (e.g. ketoprofen) for plasma protein binding sites. Plasma clearance of salicylic acid has been reported to increase in combination with corticosteroids, possibly due to induction of metabolism of salicylic acid. Concurrent use with other NSAIDs is not recommended, because of increased risk of gastro-intestinal ulcerations. Do not use in combination with veterinary medicinal products known to have anticoagulant properties.

3.9 Administration routes and dosage

Oral use, in drinking water or milk replacer

Calves: 40 mg sodium salicylate per kg body weight once daily, for 1 to 3 days.
Pigs: 35 mg sodium salicylate per kg of body weight per day, for 3 to 5 days.

Based on the recommended dose and the number and weight of animals to be treated, the exact daily concentration of the veterinary medicinal product should be calculated according to the following formula:

$$\frac{\text{.....mg veterinary medicinal product/kg body weight/day} \times \text{average body weight (kg) of animals to be treated}}{\text{average daily water/milk replacer consumption (l) per animal}} = \text{.... mg veterinary medicinal product per litre of drinking water / milk replacer}$$

When the veterinary medicinal product is administered via the milk replacer, it may be dissolved in water together with the milk replacer powder. Stirring for 3 minutes is recommended.

The maximum solubility of the veterinary medicinal product in water is approximately 250 g/litre. The maximum solubility of the veterinary medicinal product in milk replacers is approximately 80 g/litre. The use of suitably calibrated weighing equipment for the administration of the calculated amount of sodium salicylate is recommended.

Medicated drinking water should be replaced every 24 hours.
The medicated milk replacer should be consumed immediately after preparation.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

See also section 3.6. In the calf, adverse reactions may occur at dosages in excess of 80 mg/kg/day or administration for more than 10 days at a dosage of 40 mg/kg/day.

In case of an acute overdose intravenous bicarbonate infusion results in a higher clearance of salicylic acid by alkalisation of the urine and may be beneficial in correcting (secondary metabolic) acidosis.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Cattle, Pigs:
Meat and offal: zero days

Not authorised for use in animals producing milk for human consumption.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:
QN02BA04.

4.2 Pharmacodynamics

Sodium salicylate is a non-steroidal anti-inflammatory drug (NSAID) and has an anti-inflammatory, analgesic and antipyretic effect. It works by inhibiting the enzyme cyclo-oxygenase which results in the decrease of the production of prostaglandin (inflammation mediator). Clinically this will be

expressed in reduction of pain, temperature decrease and lessening of local manifestations such as redness and swelling.

4.3 Pharmacokinetics

Orally administered salicylates are rapidly absorbed by passive diffusion, in part from the stomach but largely from the anterior part of the small intestine.
Sodium salicylate is distributed well across the different tissues. Metabolism occurs primarily in the endoplasmic reticulum and the mitochondria of the liver cells. Excretion takes place mainly through urine and urinary pH plays a major role in the elimination. Low urinary pH and poor renal function leads to an increased half-life of the veterinary medicinal product.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

No information is available on potential interactions or incompatibilities of this veterinary medicinal product administered orally by mixing into drinking water or liquid feed containing biocidal products, feed additives or other substances used in drinking water.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 30 months
Shelf life after first opening the immediate packaging: 3 months
Shelf life after reconstitution in drinking water according to directions: 24 hours
Shelf life after reconstitution in milk replacer according to directions: 6 hours.

5.3 Special precautions for storage

This veterinary medicinal product does not require any special temperature storage conditions.
Store in the original package.
Once opened, store below 25°C and keep the bag tightly closed in order to protect from light and moisture.
Do not use in drinking water above 25°C.

5.4 Nature and composition of immediate packaging

Bags consisting of the following materials:
The 100 g package is a multi-layer bag with low density polyethylene inner layer. 10 bags are packed in one cardboard box.
The 1.0 kg and 5.0 kg bags are multi-layered and have an inner layer made of polyethylene.
Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

V.M.D. n.v.

7. MARKETING AUTHORISATION NUMBER(S)

8. DATE OF FIRST AUTHORISATION

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER/ IMMEDIATE PACKAGE

Cardboard box 10x100g
Plastic bag of 1 kg and 5 kg (there is no outer package for the 1 and 5 kg)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

VETOSPIRIN 1000 mg/g powder for use in drinking water/milk for cattle and pigs
(NL, BE, DE, EE, ES, HU, LV, LT, PL, PT, RO)
VETOSPIRINE 1000 mg/g powder for use in drinking water/milk (FR)

2. STATEMENT OF ACTIVE SUBSTANCES

Sodium salicylate 1000 mg/g

3. PACKAGE SIZE

10 x 100 g
1 kg
5 kg

4. TARGET SPECIES

Cattle (Calves), pigs

5. INDICATIONS

For OTC products <only for France>
Calves: Supportive treatment of pyrexia in acute respiratory disease, in combination with appropriate (e.g. anti-infective) therapy if necessary.
Pigs: For the treatment of inflammation in combination with appropriate (e.g. anti-infective) therapy if necessary.

6. ROUTES OF ADMINISTRATION

Oral use, in drinking water or milk replacer.

7. WITHDRAWAL PERIODS

Withdrawal period:
Cattle, Pigs:
Meat and offal: zero days

8. EXPIRY DATE

Shelf-life after first opening: 3 months; once opened use by…
Once reconstituted in drinking water use within 24 hours.
Once reconstituted in milk replacer use within 6 hours.

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Store in the original package.
Once opened, store below 25°C and keep the bag tightly closed in order to protect from light and moisture.
Do not use in drinking water above 25°C.

10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use.

11. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

V.M.D. n.v.

14. MARKETING AUTHORISATION NUMBERS

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

100 g plastic bag

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

VETOSPIRIN 1000 mg/g powder for use in drinking water/milk for cattle and pigs
(NL, BE, DE, EE, ES, HU, LV, LT, PL, PT, RO)
VETOSPIRINE 1000 mg/g powder for use in drinking water/milk (FR)

100 g

2. STATEMENT OF ACTIVE SUBSTANCES

Sodium salicylate 1000 mg/g

3. TARGET SPECIES

Cattle (Calves), pigs

4. ROUTES OF ADMINISTRATION

Oral use, in drinking water or milk replacer use
Read the package leaflet before use.

5. WITHDRAWAL PERIODS

Withdrawal period:
Cattle, Pigs:
Meat and offal: zero days

6. EXPIRY DATE

Exp. {mm/yyyy}
Shelf-life after first opening: 3 months; once opened use by… (to be completed by the user)
Once reconstituted in drinking water use within 24 hours.
Once reconstituted in milk replacer use within 6 hours.

7. SPECIAL STORAGE PRECAUTIONS

Store in the original package.
Once opened, store below 25°C and keep the bag tightly closed in order to protect from light and moisture.
Do not use in drinking water above 25°C.

8. NAME OF THE MARKETING AUTHORISATION HOLDER

V.M.D. n.v.

9. BATCH NUMBER

Lot {number}

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

VETOSPIRIN 1000 mg/g powder for use in drinking water/milk for cattle and pigs
(NL, BE, DE, EE, ES, HU, LV, LT, PL, PT, RO)
VETOSPIRINE 1000 mg/g powder for use in drinking water/milk (FR)

2. Composition

Each gram contains:

Active substance:
Sodium salicylate 1000 mg

White crystalline powder or small colourless flakes

3. Target species

Cattle (Calves), pigs

4. Indications for use

Calves: Supportive treatment of pyrexia in acute respiratory disease, in combination with appropriate (e.g. anti-infective) therapy if necessary.
Pigs: For the treatment of inflammation in combination with appropriate (e.g. anti-infective) therapy if necessary.

5. Contraindications

Do not use in case of severe hypoproteinaemia, liver or kidney disorder
Do not use sodium salicylates in neonates or calves less than 2 weeks of age.
Do not use in piglets of less than 4 weeks of age.
Do not use in cases of hypersensitivity to the active substance.
Do not use in case of gastrointestinal ulcerations and chronic gastrointestinal disorders.
Do not use in case of malfunction of the hematopoietic system, coagulopathies, haemor-rhagic diathesis.

6. Special warnings

Special precautions for safe use in the target species:
Given that sodium salicylate may inhibit clotting of blood, it is recommended that elective surgery should not be performed on animals within 7 days after the end of treatment.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This veterinary medicinal product may cause hypersensitivity reactions. People with known hypersensitivity (allergies) to sodium salicylate or related substances (e.g. aspirin) should avoid contact with the veterinary medicinal product. Wash hands after use.

If after accidental contact rash occurs, seek medical advice and show the package leaflet. Swelling of the face, lips or eyes or difficulty in breathing are more serious symptoms that require urgent medical attention.
Do not smoke, eat or drink during handling.

This veterinary medicinal product may cause irritation of the skin, eyes and respiratory tract. Direct contact with the skin and eyes, and inhalation of the powder should be avoided. It is recommended to wear protective gloves (e.g. rubber or latex), safety glasses, and an appropriate dust mask (e.g. disposable half-mask respirator conforming to European Standard EN149). In case of accidental dermal exposure wash skin immediately with water. In the event of accidental eye contact wash the eyes with plenty of water for 15 minutes and seek medical advice if irritation persists.

Pregnancy and lactation:
Do not use during pregnancy and lactation.
Laboratory studies in rats have shown evidence of teratogenic and foetotoxic effects.
Salicylic acid penetrates the placenta and is excreted in the milk. Since the half-life in new-borns is longer, symptoms of toxicity may occur much faster. In addition, the aggregation of platelets is slowed down and the bleeding time is prolonged, which is an unfavourable situation during dystocia or caesarean section. Some studies also indicate that delivery is delayed.

Interaction with other medicinal products and other forms of interaction:
Concurrent administration of potentially nephrotoxic drugs (e.g. aminoglycosides) should be avoided. Salicylic acid is highly plasma (albumin) bound and competes with a variety of compounds (e.g. ketoprofen) for plasma protein binding sites. Plasma clearance of salicylic acid has been reported to increase in combination with corticosteroids, possibly due to induction of metabolism of salicylic acid. Concurrent use with other NSAIDs is not recommended, because of increased risk of gastro-intestinal ulcerations. Do not use in combination with drugs known to have anticoagulant properties.

Overdose:
In the calf, adverse reactions may occur at dosages in excess of 80 mg/kg/day or administration for more than 10 days at a dosage of 40 mg/kg/day.
In case of an acute overdose intravenous bicarbonate infusion results in a higher clearance of salicylic acid by alkalisation of the urine and may be beneficial in correcting (secondary metabolic) acidosis.

Major incompatibilities:
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

No information is available on potential interactions or incompatibilities of this veterinary medicinal product administered orally by mixing into drinking water potential interactions containing biocidal products, feed additives or other substances used in drinking water.

7. Adverse events

Cattle (calves) and pigs:

Undetermined frequency (cannot be estimated from available data) :	Gastrointestinal irritation[A] ,Tarry or black stool, Digestive tract haemorrhage Polydipsia Prolonged bleeding [B]

[A] Especially in animals with pre-existing gastro-intestinal disease.
[B] Reversible inhibition of normal blood clotting; effect will diminish within approximately 7 days

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}

8. Dosage for each species, routes and method of administration

Oral use, in drinking water or milk replacer

Calves: 40 mg sodium salicylate per kg body weight once daily, for 1 to 3 days.
Pigs: 35 mg sodium salicylate per kg of body weight per day, for 3 to 5 days.

Based on the recommended dose and the number and weight of animals to be treated, the exact daily concentration of the veterinary medicinal product should be calculated according to the following formula:

$$\frac{\text{.....mg veterinary medicinal product/kg body weight/day} \times \text{average body weight (kg) of animals to be treated}}{\text{average daily water/milk replacer consumption (l) per animal}} = \text{.... mg veterinary medicinal product per litre of drinking water /milk replacer}$$

When the veterinary medicinal product is administered via the milk replacer, it can be dissolved at the same time as the milk replacer powder. Stirring for 3 minutes is recommended

The maximum solubility of the veterinary medicinal product in water is approximately 250 g/litre. The maximum solubility of the veterinary medicinal product in milk replacers is approximately 80 g/ litre.
The use of suitably calibrated weighing equipment for the administration of the calculated amount of sodium salicylate is recommended.
Medicated drinking water should be replaced every 24 hours.
The medicated milk replacer should be consumed immediately after preparation.

9. Advice on correct administration

Not applicable.

10. Withdrawal periods

Cattle, Pigs:
Meat and offal: zero days

Not authorised for use in animals producing milk for human consumption.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special temperature storage conditions.
Store in the original package.
Once opened, store below 25°C and keep the bag tightly closed in order to protect from light and moisture.

Do not use in drinking water above 25°C

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life of the veterinary medicinal product as packaged for sale: 30 months
Shelf life after first opening the immediate packaging: 3 months
Shelf life after reconstitution in drinking water according to directions: 24 hours
Shelf life after reconstitution in milk replacer according to directions: 6 hours.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Cardboard box with 10 x 100 g bags.
Bags with 1 x 1.0 kg or 1 x 5.0 kg.
Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

{DD/MM/YYYY}

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release:
V.M.D. n.v.
Hoge Mauw 900
2370 Arendonk
Belgium

Local representatives and contact details to report suspected adverse reactions:

17. Other information